• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Omalizumab relieves symptoms in chronic idiopathic urticaria

bys25qthea
February 27, 2013
in Chronic Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

[tabs tab1=”2MM Rundown” tab2= “2MM Full Report”]

[tab]

Image: PD

1. Omalizumab alleviated itchiness and reduced hives in patients with chronic idiopathic urticaria refractory to H1-antihistamine therapy.

2. Serious adverse events are more common with higher doses, to the limited extent of safety evaluations in this study.

Based on a phase-3 clinical study published today, omalizumab shows promise for alleviating symptoms in chronic idiopathic urticaria. This condition can significantly impact quality of life, especially if the itch is persistent and resistant to H1-antihistamines.

RELATED REPORTS

2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]

Safety of investigational vaccines against human immunodeficiency virus

#VisualAbstract: Remibrutinib Relieves Itching and Hives in Chronic Spontaneous Urticaria

The small size of this study precludes any definitive safety conclusions. However, omalizumab has an established safety profile, and is approved for moderate-to-severe persistent asthma with a dosing regimen of 150-375 mg SC every 2-4 weeks — higher than the regimen used in this study. Clinicians might rely on this safety profile to prescribe omalizumab off-label to patients with urticaria that is severe and refractory enough to warrant use of this expensive medication.

Click to read the study in NEJM

[/tab]

[tab]

Image: PD

1. Omalizumab alleviated itchiness and reduced hives in patients with chronic idiopathic urticaria refractory to H1-antihistamine therapy.

2. Serious adverse events are more common with higher doses, to the limited extent of safety evaluations in this study.

This [randomized, phase 3] trial evaluates the use of omalizumab in treating chronic idiopathic urticaria. Participants with H1-antihistamine resistant symptoms were randomized into four groups receiving either placebo or omalizumab at doses of 75 mg, 150 mg, or 300 mg.

Groups receiving 150 mg and 300 mg of omalizumab saw significant improvements in weekly itch-severity scores, with mean changes of -8.1±6.4 (p=0.001) and -9.8±6.0 (p<0.001) from baseline, respectively. The group receiving 75 mg of omalizumab (mean change -5.9±6.5, P=0.46) did not improve significantly compared to the placebo group (mean change -5.1±5.6). The regimen was also effective in reducing urticaria with a higher proportion of patients hives-free at week 12 (10% placebo, vs. 18%, 23%, and 53% for each omalizumab dosing regimen).

Serious adverse events were most common (6%) in the group receiving 300 mg omalizumab. However, the study was too small to draw any definitive conclusions regarding safety.

In sum: Based on this phase-3 clinical study, omalizumab shows promise for alleviating symptoms in chronic idiopathic urticaria. This condition can significantly impact quality of life, especially if the itch is persistent and resistant to H1-antihistamines.

The small size of this study precludes any definitive safety conclusions. However, omalizumab has an established safety profile, and is approved for moderate-to-severe persistent asthma with a dosing regimen of 150-375 mg SC every 2-4 weeks — higher than the regimen used in this study. Clinicians might rely on this safety profile to prescribe omalizumab off-label to patients with urticaria that is severe and refractory enough to warrant use of this expensive medication.

Click to read the study in NEJM

By Joe Liu and Mitalee Patil

More from this author: New device reduces acid exposure in gastroesophageal reflux disease, Neurostimulation beneficial in Parkinson’s disease with early motor complications, Rivaroxaban has no net clinical benefit over enoxaparin for thromboprophylaxis in acutely ill patients, Long term functional outcomes similar with surgery, radiotherapy in prostate cancer patients

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. Content is produced in accordance with fair use copyrights solely and strictly for the purpose of teaching, news and criticism. No benefit, monetary or otherwise, is realized by any participants or the owner of this domain.

[/tab]

[/tabs]

Tags: dermatologyH1-antihistamineOmalizumaburticaria
Previous Post

Aneurysm diameter useful in determining frequency of surveillance

Next Post

Ondansetron (Zofran) is safe for treatment of nausea in pregnancy

RelatedReports

2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]
Pharma

2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]

May 12, 2025
Combined immunotherapy may improve survival in metastatic pancreatic cancer
Infectious Disease

Safety of investigational vaccines against human immunodeficiency virus

April 29, 2025
#VisualAbstract: Remibrutinib Relieves Itching and Hives in Chronic Spontaneous Urticaria
StudyGraphics

#VisualAbstract: Remibrutinib Relieves Itching and Hives in Chronic Spontaneous Urticaria

March 19, 2025
Rapid growth of medical artificial intelligence technology usage identified from insurance claims analysis, yet major barriers to widespread adoption remain
Chronic Disease

Remibrutinib alleviates symptoms in chronic spontaneous urticaria resistant to H1-antihistamines

March 13, 2025
Next Post

Ondansetron (Zofran) is safe for treatment of nausea in pregnancy

Transcatheter aortic valve replacement (TAVR) for severe aortic stenosis

CABG leads to fewer MIs and repeat revascularization vs. stenting

CABG leads to fewer MIs and repeat revascularization vs. stenting

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Weighted vests and resistance training confer similar outcomes for bone density in the elderly
  • Breast cancer survivors may have a lower risk of Alzheimer’s dementia
  • Evaluating scar outcomes in pediatric burn patients following skin grafting 
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.